[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dongguan People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100651079","stupp-regimen-with-or-without-lenvatinib-for-newly-diagnosed-glioblastoma-with-mgmt-promoter-methylation-100651079",false,"NCT07754734","STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation","STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation: A Multicenter, Randomized Phase II Clinical Trial","Inclusion Criteria:\n\n* Newly diagnosed GBM confirmed by post-op pathology\u002Fbiopsy, MGMT promoter methylation positive, no prior RT or chemo.\n* Surgery\u002Fbiopsy ≤ 21 days before enrollment.\n* Age 18-75 years any gender.\n* KPS ≥ 70.\n* Organ function (no blood components or growth factors within 14 days):\n\n  1. ANC ≥ 1.5 × 10⁹\u002FL; PLT ≥ 100 × 10⁹\u002FL; Hb ≥ 90 g\u002FL.\n  2. Total bilirubin ≤ 1.5 × ULN.\n  3. ALT, AST ≤ 3 × ULN.\n  4. Serum creatinine ≤ 1.5 × ULN or CrCl ≥ 50 mL\u002Fmin.\n* Life expectancy ≥ 12 weeks.\n* Stable or tapering corticosteroid dose for 14 days.\n* Voluntary participation, signed informed consent, and good compliance.\n\nExclusion Criteria:\n\n* Allergy to Lenvatinib, TMZ, or components.\n* Other malignancies within 5 years or concurrent, or prior anti-tumor therapy.\n* Concurrent participation in another clinical trial (except observational).\n* Comorbidities interfering with treatment:\n\n  1. Grade 4 non-hematological toxicity (except hair loss, nausea, vomiting).\n  2. Conditions interfering with oral drugs (dysphagia, chronic diarrhea, bowel obstruction).\n* Evidence of increased intracranial pressure (midline shift \\> 5 mm, papilledema, vomiting, decreased consciousness).\n* History of drug\u002Falcohol abuse.\n* Pregnancy or lactation.\n* Other conditions judged by the investigator (e.g., unstable heart\u002Fkidney disease, uncontrolled diabetes, mood disorders).","ALL","18 Years","75 Years",{"count":20,"type":21},138,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To compare the efficacy and safety of Lenvatinib combined with the standard Stupp regimen versus the standard Stupp regimen alone in the treatment of newly diagnosed glioblastoma with MGMT promoter methylation positive.",[27,28,29],"Glioma","Glioblastoma (GBM)","MGMT-Methylated Glioblastoma",[31,32,33,34],"Stupp regimen","Lenvatinib","phase II clinical trial","glioblastoma and MGMT promoter methylation","NOT_YET_RECRUITING","2026-08-06",{"date":38,"type":39},"2026-08-10","ACTUAL",{"date":38,"type":21},{"date":42,"type":21},"2029-07-31",{"name":44,"class":45},"Dongguan People's Hospital","OTHER_GOV",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100644941","phase-2-mrg003-plus-toripalimab-versus-toripalimab-as-neoadjuvant-therapy-for-pd-l1-positive-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma-100644941","NCT07677475","MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma","MRG003 (Becotatug Vedotin) Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: A Multicenter, Prospective, Randomized, Controlled Phase II Trial","1. Histologically or cytologically confirmed head and neck squamous cell carcinoma (HNSCC), PD-L1 positive (CPS ≥ 1)\n2. Treatment-naïve, pathologically confirmed stage III-IVA resectable non-oropharyngeal HNSCC (oral cavity, larynx, hypopharynx) OR HPV-negative oropharyngeal SCC, OR HPV-positive stage III T4N0-2 resectable oropharyngeal cancer (AJCC 8th edition)\n3. No prior antitumor treatment (radiotherapy, chemotherapy, targeted therapy, or immunotherapy)\n4. Age 18 to 70 years\n5. ECOG performance status 0 or 1\n6. Adequate organ function within 14 days before first dose (no blood products or growth factors within 14 days):\n\n   * ANC ≥ 1.0 × 10⁹\u002FL, Hb ≥ 90 g\u002FL, PLT ≥ 75 × 10⁹\u002FL\n   * ALT\u002FAST ≤ 1.5 × ULN, total bilirubin ≤ 1.5 × ULN, ALP \\\u003C 2.5 × ULN\n   * CrCl ≥ 50 mL\u002Fmin (Cockcroft-Gault)\n   * APTT and INR ≤ 1.5 × ULN\n7. At least one measurable lesion per RECIST 1.1\n8. Life expectancy ≥ 12 weeks\n9. Female subjects of childbearing potential and male subjects with reproductive potential must use medically accepted contraception during treatment and for 3 months after last dose\n10. Voluntary signed informed consent, good compliance, willing to undergo follow-up","70 Years",{"count":55,"type":21},65,[24],"This is a multicenter, prospective, randomized, controlled Phase II trial evaluating the safety and efficacy of MRG003 (Becotatug vedotin) combined with Toripalimab versus Toripalimab alone as neoadjuvant therapy for PD-L1-positive, resectable locally advanced head and neck squamous cell carcinoma. A total of 65 subjects are planned (43 experimental, 22 control). The experimental arm receives two cycles of MRG003 (Becotatug vedotin) 2.0 mg\u002Fkg intravenously on Day 1 followed by Toripalimab 240 mg intravenously on Day 1 every 3 weeks, while the control arm receives two cycles of Toripalimab 240 mg alone. After neoadjuvant therapy, both arms undergo radical surgery 3-4 weeks later, followed by risk-adapted adjuvant radiotherapy or chemoradiotherapy with concurrent Toripalimab (3 cycles) and then 12 cycles of adjuvant Toripalimab maintenance. The primary endpoint is the major pathological response rate.",[59],"Head and Neck Squamous Cell Carcinoma",[61,62,63,64],"MRG003","Vebecototagene Autoleucovorin","Toripalimab","Neoadjuvant Therapy","2026-08-04",{"date":67,"type":39},"2026-08-05",{"date":38,"type":21},{"date":70,"type":21},"2029-06-30",{"name":44,"class":45},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100641669","phase-2-chidamide-venetoclax-azacitidine-and-homoharringtonine-for-high-risk-fit-aml-100641669","NCT07643636","Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML","A Single-arm, Single-center Clinical Trial Evaluating the Efficacy and Safety of a Regimen Combining Chidamide With Venetoclax, Azacitidine, and Homoharringtonine in the Treatment of Intermediate- to High-risk Fit AML Patients","Inclusion Criteria:\n\n1. Newly diagnosed fit-AML patients classified per the World Health Organization (WHO) classification criteria.\n2. Age ranging from 18 to 60 years, no restriction on gender.\n3. No prior anti-AML systemic therapy after AML diagnosis; cytoreductive treatment (e.g., hydroxyurea or cytarabine at a daily dose \\\u003C1.0 g) is permitted as exception.\n4. Estimated overall survival ≥12 weeks.\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤3 points.\n6. Renal function: calculated creatinine clearance (CrCl) ≥30 mL\u002Fmin.\n7. Hepatic function: alanine aminotransferase (ALT) \\\u003C5× upper limit of normal (ULN); total bilirubin \\\u003C3× ULN.\n8. Able to provide written informed consent and understand as well as comply with all study-specified procedures.\n\nExclusion Criteria:\n\n1. Patients stratified as favorable-risk AML defined by NCCN Guidelines 2022, including cytogenetic aberrations: t(8;21)(q22;q22.1); RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11.\n2. Confirmed acute promyelocytic leukemia (APL). AML complicated with central nervous system (CNS) leukemia infiltration.\n3. Cardiac function exceeding NYHA functional class II.\n4. Confirmed human immunodeficiency virus (HIV) infection or other uncontrolled clinically significant comorbidities, including but not limited to:\n\n   * Uncontrolled or active systemic infection (viral, bacterial or fungal); ② Concurrent second primary malignancy requiring urgent clinical intervention.\n\n6\\. Patients unable to receive oral chidamide and\u002For venetoclax administration. 7. Known hypersensitivity to any investigational product. 8. Pregnant or breastfeeding female subjects. 9. Inability to understand or adhere to the study protocol requirements. 10.Subjects deemed unsuitable for enrollment at the investigator's discretion","60 Years",{"count":82,"type":21},46,[24],"This study aims to explore a superior first-line induction remission regimen by incorporating Chidamide into the modified VAH chemotherapy combined with targeted therapy regimen, leveraging its dual epigenetic modulation mechanism.",[86],"AML (Acute Myeloid Leukemia)","2026-06-16",{"date":89,"type":39},"2026-06-18",{"date":91,"type":21},"2026-06-30",{"date":93,"type":21},"2029-06-01",{"name":44,"class":45},""]